GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infinity Pharmaceuticals Inc (OTCPK:INFIQ) » Definitions » Median PS Value
中文

Infinity Pharmaceuticals (Infinity Pharmaceuticals) Median PS Value : $0.00 (As of Apr. 24, 2024)


View and export this data going back to 2000. Start your Free Trial

Infinity Pharmaceuticals Median PS Value Definition

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Infinity Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.028. Infinity Pharmaceuticals's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2024-04-24), Infinity Pharmaceuticals's share price is $0.0001. Infinity Pharmaceuticals's Median PS Value is $0.00. Therefore, Infinity Pharmaceuticals's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Infinity Pharmaceuticals's Median PS Value or its related term are showing as below:

INFIQ's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.66
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Infinity Pharmaceuticals Median PS Value Historical Data

The historical data trend for Infinity Pharmaceuticals's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infinity Pharmaceuticals Median PS Value Chart

Infinity Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Infinity Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Infinity Pharmaceuticals's Median PS Value

For the Biotechnology subindustry, Infinity Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infinity Pharmaceuticals's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infinity Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Infinity Pharmaceuticals's Price-to-Median-PS-Value falls into.



Infinity Pharmaceuticals Median PS Value Calculation

Infinity Pharmaceuticals's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.028*0
=0.00

10-Year Median PS Ratio is 0.
Infinity Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.028.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Infinity Pharmaceuticals  (OTCPK:INFIQ) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Infinity Pharmaceuticals's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.0001/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Infinity Pharmaceuticals Median PS Value Related Terms

Thank you for viewing the detailed overview of Infinity Pharmaceuticals's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Infinity Pharmaceuticals (Infinity Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1100 Massachusetts Avenue, Floor 4, Cambridge, MA, USA, 02138
Infinity Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology related treatments. The company operates in only one segment which is drug development.
Executives
Adelene Q Perkins director, officer: President & CEO C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Stephane Peluso officer: Chief Scientific Officer 1100 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Brian Schwartz director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Robert Jr. Ilaria officer: Chief Medical Officer 1100 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIDGE MA 02138
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Richard Gaynor director C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Jeffery Kutok officer: Chief Scientific Officer 784 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Samuel Agresta officer: Chief Medical Officer 784 MEMORIAL DR., CAMBRIDGE MA 02139
David W Beier director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Lawrence E Bloch officer: EVP, CFO & CBO
Michael Kauffman director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Michael C Venuti director

Infinity Pharmaceuticals (Infinity Pharmaceuticals) Headlines

From GuruFocus